Guardant Health SEC Filings

Guardant Health Director Myrtle S. Potter reported multiple securities transactions on June 18, 2025:

• Disposed of 26 shares of Common Stock at $49.47 per share, retaining direct ownership of 18,154 shares
• Acquired new stock options for 6,833 shares with exercise price of $50.57, expiring June 18, 2035
• Received 4,203 Restricted Stock Units (RSUs) at $0 cost basis

Both the stock options and RSUs vest in full on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs earlier. The transactions were reported through Form 4 filing, with attorney John G. Saia signing on Potter's behalf on June 20, 2025.

Guardant Health director Roberto Mignone received new equity compensation grants on June 18, 2025, consisting of:

• Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57 per share, expiring June 18, 2035
• Restricted Stock Units (RSUs): 4,203 RSUs at zero cost basis

Both grants feature a one-year vesting schedule, becoming fully vested on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs first. The compensation package appears to be standard director remuneration, filed as required under SEC Section 16(a) regulations. The filing was completed by John G. Saia as attorney-in-fact for Mignone on June 20, 2025.

Guardant Health Director Steve E. Krognes received new equity compensation grants on June 18, 2025, consisting of:

• Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57 per share, exercisable until June 18, 2035
• Restricted Stock Units (RSUs): 4,203 RSUs at zero cost basis

Both grants feature a one-year cliff vesting schedule, maturing on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs first. The compensation package appears to be part of standard director compensation. The filing was submitted by John Saia as attorney-in-fact for Krognes on June 20, 2025.

Guardant Health Director Meghan V. Joyce received new equity compensation grants on June 18, 2025, consisting of:

• Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57, fully vesting after one year on June 18, 2026 (or next annual stockholders meeting if earlier). The options expire on June 18, 2035.
• Restricted Stock Units (RSUs): 4,203 RSUs granted at $0 exercise price, with the same one-year vesting schedule as the stock options.

This Form 4 filing, signed by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combination of options and RSUs aligns the director's interests with shareholders while providing both upside potential through options and guaranteed value through RSUs, subject to vesting requirements.

Director Manuel Hidalgo Medina of Guardant Health [GH] received new equity compensation grants on June 18, 2025, consisting of:

• Stock Options: Granted 6,833 options to buy common stock at an exercise price of $50.57, which vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first. The options expire on June 18, 2035.
• Restricted Stock Units (RSUs): Awarded 4,203 RSUs that vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first.

This Form 4 filing, submitted by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combined awards suggest continued board engagement and alignment with shareholder interests through both performance-based options and time-vested RSUs.

Guardant Health director Vijaya Gadde received new equity compensation grants on June 18, 2025, consisting of:

• Stock options to purchase 6,833 shares of common stock at an exercise price of $50.57 per share, expiring June 18, 2035
• 4,203 Restricted Stock Units (RSUs) with no exercise price

Both the stock options and RSUs will fully vest on the earlier of: (1) the one-year anniversary of the grant date (June 18, 2025) or (2) the date of the next annual stockholders meeting. This equity compensation package appears to be part of standard director compensation. The Form 4 was filed by John G. Saia as attorney-in-fact for Vijaya Gadde on June 20, 2025.

Guardant Health Director Ian T. Clark reported multiple securities transactions on June 17-18, 2025:

• Disposed of 6,672 shares of common stock at an average price of $48.38 per share from the Thornton-Clark Family Trust
• Received a new stock option grant for 6,833 shares with exercise price of $50.57, vesting in full on June 18, 2025 or next annual stockholders meeting
• Granted 5,092 restricted stock units (RSUs) vesting in full on June 18, 2025 or next annual stockholders meeting

Following these transactions, Clark retains 9,851 shares indirectly through the family trust, plus the new equity awards. The stock sale was executed in multiple transactions within a $0.03 price range.

Guardant Health, Inc. (GH) filed a Form 144 notice for a planned sale of restricted stock that recently vested. The filing discloses that 3,213 shares of GH common stock are expected to be sold through broker Charles Schwab & Co., Inc. on or about 18 June 2025. The estimated aggregate market value of the proposed sale is $158,947. Compared with the company’s 123,888,045 shares outstanding, the transaction represents roughly 0.0026 % of total shares, indicating a de-minimis impact on the public float.

The seller—identified in the filing as Musa Tariq—acquired the shares on 15 June 2025 via the lapse of restrictions on equity compensation. Over the past three months Mr. Tariq has sold an additional 348 shares of Guardant Health stock across three transactions, generating $14,910 in gross proceeds. No relationship to the issuer is specified in the document, and the form states that the filer is unaware of any non-public material adverse information.

Because Form 144 covers proposed sales under Rule 144 and does not obligate the insider to complete the trade, investors typically view such filings as information events rather than firm commitments. Given the small size of the sale relative to Guardant Health’s market capitalization, the filing is unlikely to exert material pressure on share price but does provide incremental insight into insider trading intentions.